# **RESEARCH ARTICLE**

# **Effectiveness of Education Interventions for the Management of Cancer Pain: A Systematic Review**

Yoon Jae Lee<sup>1,2</sup>, Min Kyung Hyun<sup>1,5\*</sup>, Yea Ji Jung<sup>1</sup>, Min Joo Kang<sup>1</sup>, Bhumsuk Keam<sup>1,3</sup>, Su-Jin Koh<sup>1,4</sup>

# Abstract

Background: Many cancer patients experience poor pain control due to various factors, including misconceptions regarding the use of opioid analgesics. For management of cancer pain, interventions involving education of both patients and physicians have been attempted. Objectives: This review aimed to assess the current evidence of the benefits of education for the management of cancer pain. Methods: We searched the Medline, EMBASE, Cochrane library, and major Korean databases to identify relevant studies. We included most study designs, but excluded case series. The primary outcomes were pain intensity and quality of life (QoL). Two reviewers assessed the risk of bias using the Cochrane's tool for RCT and Risk of Bias Assessment tool for Non-randomized Studies (RoBANS) for non-randomized studies, independently. Results: After extensive searches, 3,324 publications were screened, and 32 studies were selected. The education interventions used in the included studies included a wide variety of education methods, but the most common method was a booklet produced for patients. Regardless of the education method used, the results of the meta-analysis were as follows. The SMDs of the most severe, average, and current pain in the RCTs were significant. The SMD of worst, average, and current pain were -0.34 (-0.55, -0.13), -0.40 (-0.64, -0.15), and -0.79 (-1.35, -0.23). In the non-randomized studies, the effects on average pain were significant, but those on worst and current pain were not. Conclusions: Education intervention reduced the pain of cancer patients. Therefore, patient education could be considered to be an effective method of cancer pain management. However, our data should be interpreted with caution, and studies using standardized protocols are needed to confirm these observations.

Keywords: Pain - analgesics - management - patient education

Asian Pac J Cancer Prev, 15 (12), 4787-4793

# Introduction

Pain is one of the most common symptoms of cancer patients. To control cancer-related pain, it is necessary to add analgesics to the treatment regimen depending on the intensity of the pain, referring to the World Health Organization (WHO)-recommended three-step analgesic ladder (WHO, 1996). However, pain management following the World Health Organization ladder results in only 75% adequate pain control (Zech et al., 1995). Recently, a total of 45% of patients reported inadequate pain control in a survey of Korean patients carried out between 2001 and 2006 (Hong et al., 2011). Narcotic analgesics commonly have to be prescribed for the proper management of severe cancer pain. However, many patients with cancer have poor pain control for several barriers, including misconceptions concerning opioids (Brant 2010). Therefore, educating both patients and practitioners assists provision of accurate information.

Allard et al. (2001) published a systematic review of the effects of educational intervention on the control of cancer pain in 2001. In addition, Bennett et al. (2009) assessed the effects of patient-based educational intervention on cancer pain in 2009. However, these studies are not recent, and so an analysis of more recent trials is needed. Therefore, this study evaluated the current evidence of the effectiveness of education intervention in the management of cancer pain by conducting an extensive systematic review and meta-analysis. Unlike previous meta-analyses, we included observational studies and non-randomized trials that assessed intervention and patient outcome.

# **Materials and Methods**

#### Literature searches

We developed a protocol for the systematic review of the effectiveness of educational intervention for the management of cancer pain. Specifically, the population, method of intervention, method of data comparison, patient outcome, study design and time (PICOST), search methods, data extraction, quality assessment, and

<sup>1</sup>National Evidence-based Healthcare Collaborating Agency, <sup>3</sup>Department of Internal Medicine, Seoul National University Hospital, <sup>4</sup>Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, <sup>2</sup>Department of Oriental Gynecology, CHA Bundang Medical Center, CHA University, Seongnam, <sup>5</sup>Department of Preventive Medicine, College of Korean Medicine, Dongguk University, Gyeongju, South Korea \*For correspondence: mk3three@gmail.com

## Yoon Jae Lee et al

meta-analysis from published studies were all reviewed. The following parameters and limitations were used: 1) Participants: cancer patients with pain; 2) Interventions: educating cancer patients about the use of analgesics to manage pain; 3) Controls: no limitations; 4) Outcomes: primary outcomes were pain intensity and quality of life (QoL). Secondary outcomes were all other patient outcomes (excluding information from caregivers); 5) Study design: all studies included a control group (for example RCT, non-randomized controlled trials, or cohort studies).

Articles published before July 27th 2012 were searched in six electronic databases, comprising three international and three Korean databases: Ovid-Medline, Ovid-Embase, Cochrane Library, KISS (http://kiss. kstudy.com), KMBASE (http://kmbase.medric.or.kr), and KoreaMed (http://www.koreamed.org). Various combinations of Mesh headings and keywords were used, including "neoplasms", "analgesics, "opioid", "morphine", "fentanyl", "oxycodone", "hydromorphone", "patient education as topic", "health education", "health knowledge, attitudes, practice", and "pain management". For more extensive searches, we also manually searched the citations within existing systematic reviews for publications reporting the effectiveness of patient-based educational interventions for the management of cancer pain.

## Study selection

The inclusion criteria were trials that investigated the effects of educational intervention on the use of analgesics in cancer patients. All included studies were published in the English or Korean language. The exclusion criteria were duplicate publications, studies that were not peer reviewed, and those that used only the assessment of the caregiver as the outcome. All studies were reviewed and selected independently by two researchers (each study was assigned to two of MK Hyun, YJ Jung, JI Shin, and MJ Kang). The titles and abstracts were reviewed, and duplicate studies or those that did not meet PICO requirements were excluded. If the title or abstract appeared to meet the PICO of this review or we could not determine its eligibility, the full text of the article was obtained and eligibility was confirmed. Discrepancies between the reviewers were resolved after discussion.

#### Data extraction

Two independent reviewers extracted data using a standardized data extraction form (each article was assigned to two of MK Hyun, YJ Lee, YJ Jung, and MJ Kang). Any discrepancies were resolved by consensus or consultation with a third reviewer. The characteristics of the studies (study design, and country of origin) and general information (inclusion/exclusion criteria of participants, intervention tools, methods of education, the individual responsible for educating, outcomes, and patient age) were extracted. The study design was classified using DAMI (study design algorithm for medical literature of intervention) developed by Kim et al. (2011).

### Quality assessment

Four authors evaluated the quality of the studies independently. The risk of bias was assessed using RoBANS [Risk of Bias Assessment Tool for Nonrandomized Studies, Kim et al. (2013)], and the tool from the Cochrane group for RCTs. In the case of disagreement between reviewers, consensus was reached after discussions between the parties. If a consensus could not be reached between the two investigators, a third party joined the discussion and agreement was reached by majority rule.

#### Meta-analysis

The outcome of the effectiveness of education was continuous, and was analyzed statistically by calculating the standardized mean difference (SMD). Randomized controlled and non-randomized trials were analyzed separately. Inverse variance methods and the randomeffects model were also used. To control for factors such as small sample size and different interventions, outcomes were synthesized as random-effects models. Results are presented as SMDs and CIs. The Review Manager (ver. 5.1; Copenhagen: The Nordic Cochrane Center, the Cochrane Collaboration, 2011) software was used for data analysis.

# Results

### Included studies

The authors reviewed the titles and abstracts of 3324 identified studies (including 1437 international and 1887 Korean studies) independently, and 2113 were excluded. The full-text publications of the remaining 79 potentially eligible studies were reviewed in detail. Of these, 47 were excluded based on the inclusion and exclusion criteria (Figure 1), and 32 were included. Twenty-five studies were RCTs, and only seventeen of these were included in the meta-analyses due to varying outcomes. Seven studies were non-randomized trials: four of these were non-randomized controlled trials, and three studies were




Figure 1. Flow Diagram of Article Selection

"before and after" studies. The most frequently used educational tool was a booklet. Education commonly comprised multiple interventions, combined with DVDs and audiotapes. Although the educational content was diverse, the most common content was a description of pain management using analgesics, and misconceptions regarding opioids. Additional content included discussions of self-control, relaxation, and individual therapy. The control groups included in the RCTs ranged from no treatment to usual program.


## Risk of bias of the included studies

Most studies were assessed as having an unclear risk of bias in the domains of random sequence generation, allocation concealment, and blinding. The methods used for random sequencing were either not reported, or were inadequate. In particular, most studies did not consider allocation concealment for appropriate performance. Therefore, the results of these studies must be interpreted with caution (Figure 2).

## Meta-analysis

Effects on cancer pain (Figure 3), Effects on the most severe pain (Fig. 3A). Most studies used the Brief Pain Inventory (BPI) pain scale. Other tools used to assess pain were 0–10 rating scales, and these results were combined into a meta-analysis of BPI. Ten studies included a meta-analysis of severe pain, including seven RCTs. The SMD of the RCTs was -0.34 (95% CI, -0.55, -0.13, p=0.001). However, in the non-randomized studies, SMD was not significant due to high levels of heterogeneity (SMD, -0.84; 95% CI, -2.05, 0.37, p=0.17).

Effects on average pain (Figure 3B). The data from 10 studies were available for a meta-analysis of average pain. The effects of educational intervention on average pain were presented in both RCTs and non-randomized studies. The SMD of average pain was -0.40 [95% CI -0.64, -0.15, p=0.002] and -0.73 [95% CI -1.40, -0.05, p=0.03] in the RCTs and non-randomized studies, respectively. However, both RCTs and non-randomized studies exhibited high levels of heterogeneity.



**Figure 2. Risk of Bias of the Included Studies.** A) Risk of Bias Graph of Included RCTs (25 trials); B) Risk of Bias Graph of Included Non-randomized Studies (7 studies)

Effects on current pain (Figure 3C). Data from only six studies were available for use in a meta-analysis of current pain. The SMD effect of education on current pain in RCTs was -0.66 [95% CI -1.09, -0.23, p=0.002]. In contrast, there was no SMD in the non-randomized studies due to high levels of heterogeneity.

## Effects on quality of life

<u>Effects on overall quality of life</u>: only two studies were included in the meta-analysis of QoL, which were by the same author and reported using EORTC QLQ\_

State or Salvareau	them at a	-	Control			Bloan Difference /. Random, 95% Ci.: Yea	std. Rean Difference M. Random, 55% Cl	A
121907	Adean 30.1	18.14	0 30 1	000 W	1211 0	Rendord, You Co., Tel	E N, SB000, 575 0	_
Nard 2088	287 27	11 3	48 315	22 1	24	4.9623,040,000		
L# 2004	530 1/2		50 280		12%	4.00 10 72 0 84 200		
Waterowski 2004	38 336		5 223	静山		-0.47 (0.78 -0.18) 200		
(ee/e 2005	121 257		11 241			-0.30 (-0.0.0.00) 200		
Valleme 2008	42 26		11 27			44668.000 20		
	110 110	42	8 585	42 1		239(032.050) 200		
10012010	35 387		48 4.65			4731418.438 201		
Sublow (RSN-CB		280		31 1		AM[ASL-213]	•	
Heleropeneity Tau <sup>4</sup> o Teoriforoxical effect 1	10.04184	# 66				and here and		
122 Non randomized								
The 200	115 278	* *	51-241	¥.)	24.	131031.070 20		
Note 2002	4 3 22		13 261			-1 01 \$1.75 -0.25 200		
Auc in 2005	24 111		1111	27 1		4.72 (22 4.16) 200		
Subscial (95% CB	11.1.1	94		68 2		484(205.037)	-	
References Taufor Reptific overall effect 2		t d'= 3	(P + 0.0030)					
Mat 1999 Ci		177		15 W		441(32), 514		
Helerogeneite Tau <sup>e</sup> n:						ere: lint if one		-
Test for overall effect 1 Test for subcrass of the			10:045	PLES			Facus (opermental) Facus (co	nut.
						Del Maria Dillare	day been had	D
State or Subercep	Education Mean 50		Contro Next 5		Wente	Stil Mean Ofference N. Ranckom, 855 C	Std. Mean Difference N. Randon, 975 C	B
1.1.1 RCTs								
Keefe 2005	\$31 2.11	41	5.45 210		183%	-2463-046-000	+	
Lu 2004	28, 181	15	171 11		87%			
Lovel 2210	208 238	37	181 23	1 40	1125	-172[-1:10]-0:23		
Rapiowski 2084	272 182	90	2.72 1.8	1 13	125%	-151-082-021	+	
Oytisia 2008	236 212	48	274 21	1 42	1015			
Valleys 2006	28 24		44 2		55%			
Ward 2009	132 238		2.43 14		14.7%			
Salatatal (55% CI)		641			74.95			
Helerogeniky, Tiw <sup>a</sup> s Testifor overall effect			=6 <i>(</i> 7=0.3	06), Ma	17%			
1.5.2 Non sendomice	ed stackes							
Autoin 2008	2.8 1.81	53	33.1.8	3 27	\$7%	1.00[1.58.0.59		
Kixon 2002	- 28 TH	18	413 1.8	1 15	61×	4.34(479,433		
Shin 2003	4.000 1.0.000	- 25	458 28	2 25	115	0.03(0.54,0.47		
	4.32 2.82			68	25.1%	47311.40, 485	•	
Hidrogenuty, Twi-	= 0.26, 01#= 7		2(7=802	1.9=72	S /			
Sectorel (95%-CD) Historypenuty, Tax*- Testfor overall effect	= 0.26, 01#= 7	84, #= 130	2094002					
Historogenuts; Tiw*: Test for overall effect Total (95% CI)	=12607=7 [2=212(P=1	84,#= 130 725		73	191.0%		•	
Historogenuty, Tiw <sup>4</sup> - Testifor overall effect Total (95% CI) Historogenety, Tiw <sup>4</sup> - Testifor overall effect	=926,079=7 (I=212(P=) =911;079=3 (I=11)(P=)	84, #= 130 725 4 38, cfs 13001)	s@+03	738 Cânj Pa	191.95 74%	#4910,34, #24	Facus epimental Facus co	Dipl.
Hidorogenuty, Tiw <sup>4</sup> - Testfor overall effect Total (99% CT) Hidorogenety, Tiw <sup>4</sup> - Testfor overall effect	=926,079=7 (I=212(P=) =911(079=3 (I=11)(P=)	84, #= 130 725 4 38, cfs 13001)	s@+03	738 Cânj Pa	191.95 74%	#4910,34, #24	11112	
Hidorogenuity, Tiw <sup>4</sup> - Testifor overall effect Fotal (95% C) Hitorogenoby, Taw <sup>4</sup> - Testifor overall effect Testifor nucleosus sh	= 0.2% (Cr# = 7 (2 = 2.12 (P = 1) = 0.11; (Cr# = 3 (2 = 3.11; (Cr# = 3 (2 = 3.11; (Cr# = 4) (2 = 3.11; (Cr# = 4) (2 = 3.11; (Cr# = 4) (2 = 3.11; (Cr# = 7) (2 = 3.11; (Cr# = 7)) (3 = 3.1	84, #=: 130 735 438, 054 13001) 1 093 12 118	(9(2+0) f=1(2=1 Contr	738 001 *+ 351 P+ \$	192.9% 74% 5%	849(034, 824 510 New Difference	Facus intermental Facuni con Sat. Menn Difference	
Hidaropenuity, Twi- Teat for overall effect Index (99% CI) Hidaropenity, Twi- Teat for overall effect Fed for overall effect Shuffy or Subgroup	= 0.28, Cr# = 7 12 = 213 (P = 1 = 0.11, Cr# = 3 12 = 3 M (P = 1 Terminet: Cr#	84, #=: 130 735 438, 054 13001) 1 093 12 118	(9(2+0) f=1(2=1 Contr	738 001 *+ 351 P+ \$	192.9% 74% 5%	849(034, 824	Facus intermental Facuni con Sat. Menn Difference	
Hidaroperuoti, Tilef- Teatrifar overall affect Total (1955-CT) Hidaroperuoti, Tilef- Teatrifar subassus ch Shufu or Subassus ch Shufu or Subassus ch Shufu or Subassus	= 0.25; Cr#= 7 12 = 212 (P = 1 = 0.11; Cr#= 3 12 = 3 19 (P = 1 Terrers Cr# Experimen Usen 50	84, #= 130 735 4 38, dfs 13001) 1 0 83 1808 1808	:9(2+0)) f:1(2:1) Contr Illean <u>S</u>	738 cong Pr ats Pr ats Pr ats Pr ats Pr	191295 745 78	449(0,34, 424 Sid Usen Difference 11, Random, 555 C	Sat. Lieve Difference N. Rander, SSAC	
Hidaroperuoti, Tikr <sup>4</sup> Feat (1995-01) Hidaroperuoti, Tikr <sup>4</sup> Feat for overall effect Feat for overall effect Feat for overall effect Study or Subgroup 1.98.1 RCTs La 2004	= 0.2%, Cr# = 7 12 + 2.12 (P + 1 + 0.11; Cr# = 3 12 = 217 (P + 1 Toperate Usen St 173 1 \$87	54, #= 130 725 130, 05 130, 05 130, 05 15 15 15	:9(*+0.) f::1(*:1 Contr INan <u>9</u> 347 20	738 cong Pa atta Pa atta 1 <u>1404</u> 3 15	191.0% 74% 7%	449(634, 424 Std. Nem Difference 17, Rondom, 955, C 497(1,52, 411)	Sat. User: Difference NX.Rondom, 555.Cl	
Historopenuity, Tilef- Feat for evenal effect Intel (95% CI) Historopensity, Talef- Feat for over all effect Feat for over all effect Study or Subarrow USE: FRCTs La 2004 Romass 2012	= 0.28, (r#=7) 12 = 212(P = 1) = 0.11, (rrP+3) 12 = 2170(P = 1) tremset: CHP. Experiment <u>Network</u> SD 120, 180 11, 0.05	54, st = 1 130 725 4 38, cts 10001) 1 6 83 16 16 16 20	:9(?+03 f:1(?=1 Contr I <u>Han 3</u> 347 20 315 27	738 cong Pa ats Pa 4 3 1984 3 1985 1	191.9% 74% 0% <u>Weight</u> 17.5% 18.7%	449(634, 424 Sid Hen Difference 1), Rondom, 95% C 407(1,52, 011 -123(1,52, 011	Sat. User: Difference NV, Random, 553-CI	
Hideroperuoti, Tilef- Teat for everal effect Inter (90% CT) Hiteroperuity, Tilef- Teat for everal effect Fried for eveneral effect Study or <u>Subarrup</u> 158.1 RCTs Lai 2004 Thomas 2012 Ion der Peet 2008	= 0.2%, Cr# = 7 12 + 2.12 (P + 1 + 0.11; Cr# = 3 12 = 217 (P + 1 Toperate Usen St 173 1 \$87	54, #= 130 725 130, 05 130, 05 130, 05 15 15 15	:9(*+0.) f::1(*:1 Contr INan <u>9</u> 347 20	738 cong Pa ats Pa 4 3 1984 3 1985 1	191.0% 74% 7%	449(0.34, 424 Sid Hen Difference IV. Rondom, 955 C 487(152, 011 -123(130, 067 -043)(276, 004	Sat. User: Difference M.Rander, SSAC	(
Historopenuity, Twi- Teatifur evenal effect Index (1955-CI) Historopensity, Twi- Teatifur overall effect Feeldin subsecut of Status or Subsymm Status of Subsymm Thomas 2012 and chir Paet 2008 Samtas (455-CI) Historopensity, Twi-	=0.25, Cr#=7 12=212(P+1) =0.11; Cr#=3 12=217(P=1) fremmen: CHP Toperment <u>Herm SD</u> 173 187 11 0.05 278 267 =0.15, CHP=5	54, #= 110 725 4 (2001) (020) (0201)	19(2+03) fo:1(2+03) Contro Illean SI 347 20 315 27 404 25	738 cont ** atta P= 4 5 1989 1 15 1 20 2 62 57	191.0% 74% 76% 17.5% 187% 34.7% 58.9%	449(0.34, 424 Sid Hen Difference IV. Rondom, 955 437(1.52, 011 -1.23(1.8, -0.61 -0.43(2.76, -0.64	Sat. User: Difference M.Rander, SSAC	
Hidanopenuts, Tiert- Teatifar einnail effect Index (90% CI) Hidanopenite), Tiert- Tiert far eine all effect Teatifar kunstesson stil Stadu um Stabigmann 1.58.1 RCTs Lai 2004 Romass 2012 ein der Peet 2008 Samthal (95% CI) Hider agemeite: Tiert-	= 0.26, Cr#= 7 [2 = 212 (P = 1 2 = 212 (P = 1 ) (2 = 219 (P = 1) formasis: CHP formasis: CHP formasi	54, #= 110 725 4 (2001) (020) (0201)	19(2+03) fo:1(2+03) Contro Illean SI 347 20 315 27 404 25	738 cont ** atta P= 4 5 1989 1 15 1 20 2 62 57	191.0% 74% 76% 17.5% 187% 34.7% 58.9%	449(0.34, 424 Sid Hen Difference IV. Rondom, 955 437(1.52, 011 -1.23(1.8, -0.61 -0.43(2.76, -0.64	Sat. User: Difference M.Rander, SSAC	
Historoperuuty, Twe's Teat for evenal effect Notar (1955-CT) Historoperuter, Twe's Teat for even all effect Teat for even all effect Teat for even all effect Teat for even all effect Statutus (1955-CT) Historoperator Twe's Teat for evenal effect 1.182 (Not-randomic	= 0.25; Cr#= 7 [2 = 212(P = 1 = 0.11; Cr#= 3 [2 = 371(P = 1 forement: Cr#= forement: Cr#= forement: foreme	54, df = 705 430, df = 10001 10000 10000 10000 10000 10000 10000 10000 10000 10000 100000 1000000	-9(P+0.3 fr:1(P=1) Contro INean 3 347 20 315 27 404 25 2(P=0.00	738 con_P+ at_P+ <u>1 180</u> 1 15 1 20 2 62 87 87 87	194.0% 74% 17.3% 10.7% 34.7% 34.9%	449 (0.34, 424 5td Nem Difference (), Rondom, 555, 01 (), 123 (1.52, 01) (), 123 (1.52, 01) (), 435 (1.52, 014 (), 435 (1.52, 014) (), 125 (1.52, 014)	Sat. Users Informace 77, Random, SSA.CI	
Historopenuity, Tiert- Teatifur einerall effect Index (1955-CT) Historopenite), Tael- Teatifur einerall effect Teatifur einerall effect Teatifur einerall effect Teatifur einerall effect Studiu of Schottea La 2004 Frames 2012 ein der Peet 2008 Samthal (45% CT) Historopenich Tae <sup>2</sup> Teatifur einerall effect	-0.25, Cr#=7 Z=212(P=1 -0.11; Cr#=3 IZ=370(P=1 Iz=370(P=1 Iz=370(P=1 Iz=370(P=1 Iz=370(P=1 Iz=370(P=1 Iz=370(P=1 Iz=370(P=1 Iz=370(P=1 Iz=370(P=1 Iz=370(P=1) Iz=370(P=1 Iz=370(P=1) Iz=	54, df = 133 755 131 cfs 131 cfs 1	-96+03 fr:16+3 Contro 1640 - 9 347 - 20 347 - 20 347 - 20 26+036 26+036 348 - 28	738 con; *, an; *, <u>an; *,</u> an; *, <u>an; *,</u> an; <u>an; *,</u> an; an; an; an; an; an; an; an; an; an;	198,0% 74% 0% 17,5% 18,7% 18,2% 19,7% 21,1%	449(0.34, 424 Std. Hern Difference (N. Rondom, 95), O 407(155, 011 -123(135, 012 -043(0.26, 004 -043(0.26, 004 -043(0.25, 004) -043(0.25, 004)	Sat. User: Difference M.Rander, SSA.CI	
Historopenuity, Tiert- Teatifur einerall effect Index (1955-CT) Historopenite), Tael- Teatifur einerall effect Teatifur einerall effect Teatifur einerall effect Teatifur einerall effect Studiu of Schottea La 2004 Frames 2012 ein der Peet 2008 Samthal (45% CT) Historopenich Tae <sup>2</sup> Teatifur einerall effect	-0.25, Cr#=7 Z=212(P=1 -0.11; Cr#=3 IZ=370(P=1 Iz=370(P=1 Iz=370(P=1 Iz=370(P=1 Iz=370(P=1 Iz=370(P=1 Iz=370(P=1 Iz=370(P=1 Iz=370(P=1 Iz=370(P=1 Iz=370(P=1) Iz=370(P=1 Iz=370(P=1) Iz=	54, df = 133 755 131 cfs 131 cfs 1	-9(P+0.3 fr:1(P=1) Contro INean 3 347 20 315 27 404 25 2(P=0.00	738 con; *, an; *, <u>an; *,</u> an; *, <u>an; *,</u> an; <u>an; *,</u> an; an; an; an; an; an; an; an; an; an;	194.0% 74% 17.3% 10.7% 34.7% 34.9%	449 (0.34, 4.24 Sid, Hen Difference (), Rondom, 95, 0 437 (1.52, 0.11 -1.23 (1.52, 0.11 -1.23 (1.52, 0.12 -4.43 (2.75, 0.04 -4.43 (2.75, 0.05 -4.43 (2.75, 0.05) -4.43 (2.75, 0.05) -4.4	Sat. User: Difference M.Rander, SSA.CI	
Historoperusty, Twe <sup>1</sup> - Teat for evenal effect Inter (1995-CT) Historoperately, Twe <sup>2</sup> - Teat for overall effect Teat for overall effect Inter Schotman Study or Schotman USL 1 RCTs Lau 2 CO4 Romass 2012 An der Peet 2008 Samthal (955-CT) Hateroperatie Study 1,582,2 Non-rendomin Lee 2008 Stat 2003	-0.25, Cr#=7 Z=212(P=1 -0.11; Cr#=3 IZ=370(P=1 Iz=370(P=1 Iz=370(P=1 Iz=370(P=1 Iz=370(P=1 Iz=370(P=1 Iz=370(P=1 Iz=370(P=1 Iz=370(P=1 Iz=370(P=1 Iz=370(P=1) Iz=370(P=1 Iz=370(P=1) Iz=	54, df = 133 755 131 cfs 131 cfs 1	-96+03 fr:16+3 Contro 1640 - 9 347 - 20 347 - 20 347 - 20 26+036 26+036 348 - 28	738 con; *, an; *, <u>an; *,</u> an; *, <u>an; *,</u> an; <u>an; *,</u> an; an; an; an; an; an; an; *, *, *, *, *, *, *, *, *, *, *, *, *,	198,0% 74% 0% 17,5% 18,7% 18,2% 19,7% 21,1%	449 (0.04, 4.24 Sid, Henn Difference 17, Rondom, 95% C 487 (1.52, 411 -1.23 (1.8), 407 -4.43 (2.76, 404 4.09 (1.25, 4.23) 0.29 (3.27, 085 -4.90 (1.82, -0.17)	Sat. Likes: Difference M. Random, SSA.CI	
Hiteroperuch, Text- Testifor energia effect Totar (95% CI) Hiteroperator, Tax/*, Testifor examination Control (1997) Statutor Schotteroperation (1982) Hiteroperator Statutor (95% CI) Hiteroperator Hiteroperator	= 0.25; Cr#=7 [2 = 212; Cr#=7 [2 = 212; Cr#=1 [2 = 213; Cr#=1 [2 = 213; Cr#=1 [10:05] [12] 187 [11] 0.05 [2 37] 283 [12] 187 [11] 0.05 [2 37] 283 [2 37] 2	54, 37 = 5 1000 725 1000 1	=====================================	750 citry P- ath	1988,0% 74% 0% 17.5% 18.7% 39.7% 39.7% 17.3% 17.3% 39.1%	449 (0.34, 4.24 Sid, Henn Difference 17, Rondom, 95% C 487 (1.52, 411 -1.23 (1.8, 407 -4.43 (2.7, 404 4.75 (1.15, 4.23) 0.29 (3.27, 085 -0.03 (1.85, -0.17)	Sat. Likes: Difference M. Random, SSA.CI	
Hidan openuity, Tiert- Teat for evenal effect Notar (195% CT) Hidan openalety, Tael & Ac- Teat for even all of Ac- Samthat (45% CT) Hidan openale Tael* Sattatu (45% CT) Hidan openale Tael* Sattatu (45% CT) Hidan openale Tael* Feat for evenal effect	= 0.25; Cr#=7 [2 = 212; Cr#=7 [2 = 212; Cr#=1 [2 = 213; Cr#=1 [2 = 213; Cr#=1 [10:05] [12] 187 [11] 0.05 [2 37] 283 [12] 187 [11] 0.05 [2 37] 283 [2 37] 2	54,87= 100 755 400001 100 100 100 100 100 100	=====================================	738 con_P+ ant_P+ d <u>3_1000</u> 1_15 1_20 2_62 3_7 5 7_25 1_16 4 1_17 4 1_17 4 1_17 4 1_17 4	195,0% 74% 0% 17,5% 16,7% 32,7% 32,7% 17,3% 17,3%	449(0.34, 424 5td Nem Difference 17, Rondon, 95% C 487(152, 011 -123(152, 011 -123(152, 012 -043(125, 012 -043(125, 012 -043(125, 012 -020(145, 020)	Sat. User: Difference M.Rander, SSACI	
Historopenoity, Tax*: Testific overall effect Total (1956-CI) Historopenoity, Tax*+	= 0.25; Cr#=7 [2 = 212; Cr#=7 [2 = 212; Cr#=1 [2 = 213; Cr#=1 [2 = 213; Cr#=1 [10:05] [12] 187 [11] 0.05 [2 37] 283 [12] 187 [11] 0.05 [2 37] 283 [2 37] 2	54, 37 = 5 1000 725 1000 1	=====================================	738 con_P+ ant_P+ d <u>3_1000</u> 1_15 1_20 2_62 3_7 5 7_25 1_16 4 1_17 4 1_17 4 1_17 4 1_17 4	195,0% 74% 0% 17,5% 16,7% 32,7% 32,7% 17,3% 17,3%	449 (0.34, 4.24 Sid, Henn Difference 17, Rondom, 95% C 487 (1.52, 411 -1.23 (1.8, 407 -4.43 (2.7, 404 4.75 (1.15, 4.23) 0.29 (3.27, 085 -0.03 (1.85, -0.17)	Sat. User: Difference M.Rander, SSACI	
Hidan openuity, Tiert- Teat for evenal effect Notar (195% CT) Hidan openalety, Tael & Ac- Teat for even all of Ac- Samthat (45% CT) Hidan openale Tael* Sattatu (45% CT) Hidan openale Tael* Sattatu (45% CT) Hidan openale Tael* Feat for evenal effect	-0.20, Cr#=7 Z=212(P=1 -0.11, Cr#=3 IZ=310(P=1 Internet: Cr# Toperate Idean 50 173 187 -11 0.05 270 263 -0.10, Cr#=5 Z=275(P=0 -0.50, Cr#=5 Z=0.50, Cr#=5 -0.50, Cr#=5 -0	54, 37 = 1 100 755 40000 10 10 10 10 10 10 10 10 10 10 10 10	19€+03 Contro 1947 20 347 20 315 27 484 25 20€=030 348 25 348 25 348 25 348 25 10€=030	738 2001; P. 3 30; P. 3 3 1 100 2 62 3 1 10 1 10 2 62 3 1 10 1 10 1 10 1 10 1 10 1 10 1 10 1	195395 745 05 17755 1075 2575 2575 2575 2575 2575 2575 2575 2	449(0.34, 424 5td Nem Difference 17, Rondon, 95% C 487(152, 011 -123(152, 011 -123(152, 012 -043(125, 012 -043(125, 012 -043(125, 012 -020(145, 020)	Sat. User: Difference M.Rander, SSACI	

**Figure 3. The Results of Meta-analysis of Cancer Pain (forest plot).** A) Most Severe Pain; B) Average pain; C) Current pain

	Country	Inclusion criteria	Exclusion criteria	No. of Patients**	Educational content	Educator	Educational tools	Control Group	Outcomes
Keefe et al., 2005	USA	<ol> <li>Advanced cancer diagnosis;</li> <li>Cancer related worst pain &gt;3;</li> <li>Life expectancy &lt;6 months;</li> <li>An or change in treatment plans;</li> <li>An or &gt;18 vorse</li> </ol>	NR	78 (41/27)	Cancer pain management, information of a variety of pain coping strategies, methods of how caregivers can help	Nurse	Booklet, videotape, audiotape	Usual care	BPI, FACT-G, Chronic Pain Self-efficacy scale, caregiver version, CSI
Lai et al., 2004	Taiwan	<ul> <li>Arges 18 years.</li> <li>Cancer-related pain during the last 2 weeks;</li> <li>Patient could communicate verbally;</li> <li>Informed natient consent.</li> </ul>	Surgery during the 2-week study period	30 (15/15)	Information and drugs for cancer pain, misconceptions of using pain medicine, methods to prevent side-effects, and wars to communicate moblems with pain and wars to communicate moblems with pain	Nurse	Booklet	Usual care	BPI, POABS-CA, CSQ-Cat, KPS
Lovell et al., 2010	Australia	<ol> <li>The second second</li></ol>	<ol> <li>Cognitive, visual, or hearing impairment; (1 2) Previous exposure to education</li> </ol>	217 (booklet, 51; video, 51; video and booklet, 61; standard care, 54)		NR	3 groups (booklet, video, and booklet and video)	Standard ceare	BQ, BPI, PMI, Uniscale for Global Quality of Life, HADS
Miaskowski et al., 2004	U.S.A	<ol> <li>Age &gt;18 years;</li> <li>Oncology outpatients;</li> <li>The use of English language;</li> <li>KPS&gt;50,</li> <li>Fain intensity &gt;2.5;</li> </ol>	No family caregiver that could participate.	(93/81)	Improving pain relief by altering the times and frequency of analgesic intake. assessment of pain, prevention of side-effects	Specially trained oncology nurse		Standard care	Pain intensity, intake of opioid analgesics
Syrjala et al., 2008	U.S.A	<ol> <li>Cancer patients with persistent pain and ambulatory status;</li> <li>Life expectancy and an expected cancer treatment duration ≥6 months;</li> <li>Age &gt;18 years;</li> </ol>	<ol> <li>Alcohol or other abuse;</li> <li>Major psychiatric diagnoses</li> </ol>	93 es (48/45)	Common barriers to pain relief, essential ways to communicate with physicians, prominent pain treatment-related symptoms, 26 common medications and other pain treatments	Nurse	Print material, video	Education of nutrition	BQ, BPI, MSAS, Mean daily opioid use, ECOG performance status, FACT-G (baseline)
Vallieres et al., 2006	Canada	<ol> <li>Age &gt;18 years;</li> <li>Receiving analgesics for pain;</li> <li>French-speaking patients;</li> <li>A history of radiation therapuy&gt;1 week</li> </ol>	Receiving strictly antalgic radiotherapy	64 (33/31)	The principles and philosophy of analgesic treatment including myths and misconceptions, a pain diary, and improving accessibility <b>0</b>	≝ 25.0	Brochure Brochure	Standard pain management 25.0	Pain levels validated by the American Pain Society
Ward et al., 2009 Ward et al., 2000	U.S.A U.S.A	<ol> <li>The ability to communicate in English;</li> <li>Age &gt;18 years; 3) Moderate to severe pain 1) Meastantic or programs way work objectived cancer;</li> <li>Cancer ranin in the last 2 weeks.</li> </ol>	Previous exposure to pain education NR	1256 (391/434/431) 43 (21/22)	Education regarding barriers (fatalism, fear of addiction or complaining, worries of potential side effects or tolerance) individually tailored information regarding pain harriers and the manacoment of side-effects	Nurse or heath ce) educators Nurse	Booklet 0 Booklet	No intervention and no assessment, or no intervention and assessment only Usual care	Pain duration, BPI, BQ-II BQ. PMI, MSEC, BPI, FACT-G
Chang et al., 2002	Taiwan	<ol> <li>D.Localized cameer: 2) Age - 18 years;</li> <li>Not currently receiving surgery, radiotherapy, or chemotherapy;</li> <li>He use of analyseiss for cancer pain;</li> <li>Schedulad för discherene</li> </ol>	Pain-related treatments	<sup>37</sup> Newl	<sup>37</sup> Newly Blaghösed with to the the armaneter the second states of the	REarch assistant	1 Booklet, Q <b>63</b>	<b>6.3</b>	BQ. BPI, medication adherence, demographic questionnaire
Van der Peet et al., 2008 Netherland	Netherland		Curative anticancer treatment before 2000	120 (62/58) <b>N</b>	Enhangement of pain knowledge, instructions on how New/Kodiaggnqsspcl.awithuttraghtmashing behavior	Beklet, CD, Bendiary	¥0.8	<b>Ferrell's Pain Off tighmaire,</b> EORTC-C3 <b>F1</b> ADS	
Thomas et al., 2012	U.S.A	<ul> <li>) The ability to read and understand English;</li> <li>(1) The ability to read and understand English;</li> <li>2) Access to a telephone;</li> <li>3) Life expectancy &gt;6 months;</li> <li>4) Pain intensity &gt;2</li> </ul>	Cognitive or psychiatric condition, or substance abuse	228 (75/coaching 64/ control/88)	The use of analgesics and non-pharmacological pain mpersystephytesion recurrence and communication of pain management.	Nurse or psychology interns	Telephone	Coaching or ual care	BQ, BPI, SF-36, FACT-G
Yildirim et al., 2009	Turkey	<ol> <li>Cancer diagnosis:</li> <li>Experiencing cancer pain &amp; currently taking at least second-step analgesics;</li> <li>Paind duration: 1 month;</li> <li>No horin metastasis;</li> <li>No horin metastasis;</li> <li>Age &gt;18 years;</li> <li>Able to communicate verbally</li> </ol>	History of surgery within 2 weeks	40 (20/20)	Comprehensive information regarding pain and the treatment of cancer-rela <b>&amp; philission</b>	31.3	31.3	Standard care 25.0	MPQ. NRS, BQ-r, KPS
R, Not reported; BQ, B ain Index; POMS-B, Pr ain Index; POMS-B, Pr	arriers Ques offile of Mox	tiomaire: BPI, Brief Pain Inventory: MSAS, Memori. od States-B; PMI, Pain Management Index; HADS, H	al Symptom Severity: FACFG, lospital Anxiety and Depression	Functional Assessmen Scale; MSEC, Medic	*NR. Not reported: BQ., Barriers Questionnaire: PPI, Brief Pain Inventory; MSAS, Memorial Symptom Severity; FACT-G, Functional Assessment of Cancer Therapy-General; MPQ, McGill Pain Questionnaire; NRS, Numeric Rating Scale; BQ-r, Barriers Questionnaire-Revised; KPS, Kamofsky Performance Status; CSI, Caregiver Strain Index; POMS-B, Profile of Mood States-B; PMI, Pain Management Index; HADS, Hospital Anxiety and Depression Scale; MSEC, Medication Side Effect Checklist; **Intervention group/Control group On CCC CCC Control group CONS-B, Profile of Mood States-B; PMI, Pain Management Index; HADS, Hospital Anxiety and Depression Scale; MSEC, Medication Side Effect Checklist; **Intervention group/Control group CO CCC CONS-B, Profile of Mood States-B; PMI, Pain Management Index; HADS, Hospital Anxiety and Depression Scale; MSEC, Medication Side Effect Checklist; **Intervention group/Control group CCC CCC CONS-B, Profile of Mood States-B; PMI, Pain Management Index; HADS, Hospital Anxiety and Depression Scale; MSEC, Medication Side Effect Checklist; **Intervention group/Control group CCC CCC CCC CCC CCC CCC CCCC CCC CCC	re: NRS, Numeric F	Rating Scale; BQ-r, I 0.02 0.02	Barriers Questionnaire-Revised; KPS. R <b>100</b> <b>0</b> <b>0</b> <b>0</b>	Kamofsky Performance Status; CSI, Careg
				Newly diag	Newly diagnosed without treatment Chemother		56.3	12.8 6.3	

Yoon Jae Lee et al

4790 Asian Pacific Journal of Cancer Prevention, Vol 15, 2014

Table 2. The Ci	haracteri	Table 2. The Characteristics of the Included Studies (non-randomized trials)	-randomi	zed trial	\$)				
	Country	Country Inclusion criteria	Exclusion	No. of	Educational content	Educator	Educational tools	Control Group	Outcomes
			criteria	patients**					
Shin et al., 2003	Korea	<ol> <li>Patients with cancer pain;</li> <li>Able to communicate in Korean;</li> <li>No other physical or psychological diseases;</li> <li>Patient informed consent;</li> <li>Age &gt;20 years;</li> </ol>	NR ases;	50 (25/25)	Cause of pain, methods of pain management, and analgesics	Nurse	Booklet and audio tape	No intervention	Pain intensity, Barriers Questionnaire
		6) The use of analgesics for cancer pain management	anagement						
Kwon et al., 2002	Korea	<ol> <li>Cancer patients ages &gt;18 years;</li> <li>Cancer pain duration &gt;2 weeks;</li> <li>The ability to read and understand</li> </ol>	NR	32 (16/16)	Information on cancer pain	Nurse	Booklet and audio tape	No intervention	Satisfaction, Patient Outcome Questionnaire, Pain intensity,
Aubin et al., 2006	Canada	<ol> <li>Life expectancy &gt;6 weeks;</li> </ol>	NR	80 (53/27)	Didactic material on pain management, a pain diary, and specific	Nurse	Video tape	Usual home care service	BPI, FPQ
		<ol><li>No cognitive impairment</li></ol>			instructions on how to react to pain				
De Wit et al., 1997	Netherland:	De Wit et al., 1997 Netherlands 1) Pain related to cancer, cancer therpy, or illness;	s; NR	209	Information and instructions regarding Trained nurse Booklet, audio cassette	<b>Frained</b> nurse	Booklet, audio cassette	Usual care	MPG, EORTC QLQ-C30,
		<ul> <li>2) Cancer pain duration ≥1 month;</li> <li>3) Life expectancy ≥3 months;</li> <li>4) The ability to read and speak Dutch;</li> </ul>		(106/103)	pain and pain management, the self-recording of pain in a pain diary, and seeking help for pain				Pain intensity, Average pain intensity
D. W	N	) Access to a telephone	Ę	101	and pain management		·		
De Witter al., 2001	Netherland	<ul> <li>De Wit et al., 2001 Netherlands 1) Pain duration &gt;1 month;</li> <li>2) Cancer related pain;</li> <li>3) Life expectancy &gt;3 months;</li> <li>4) The ability to read and speak Dutch;</li> <li>5) Access to a telephone</li> <li>6) Not residing in a nursing home or retirement home</li> </ul>	NK home	104 (53/51)	information and instructions to improve the knowledge of pain, enhanced motivation to adhere to treatment, pain monitoring, and stimulating help-seeking behavior	Nurse	Audio tape, booklet	Usual care	EUKIC QLQ-C30
*NR, Not reported; BF	I, Brief Pain I	*NR, Not reported; BPI, Brief Pain Inventory; FPQ, Family Pain Questionnaire; MPQ, McGill Pain Questionnaire; **Intervention group/Control group	McGill Pain (	Questionnair	**Intervention group/Control group				

Ū 2 • Ê Ē ¢

DOI:http://dx.doi.org/10.7314/APJCP.2014.15.12.4787 Educational Interventions to Improve Management of Cancer Pain L C30 (European Organization for Research

and Treatment of Cancer Quality of Life Questionnaire). The SMD of quality of life was 0.07 (95% CI -0.15, -0.29, p=0.82) (data not shown). Educational intervention did not result in improved QoL of cancer patients, although these results are limited by the inclusion of data from only two small studies.

Effects on pain: the SMD of pain based on the EORTC questionnaire 100.00.07 (95% CI -0.55, -0.41, p=0.78). Patient education did not result in significant differences in physical functioning, role functioning, cognition functioning, fatigue, nausea and vomiting or sleep disturbance (data not shown). Effects on the functional assessment of

cancer therapy - general (F50.0-G): only two studies were included in this meta-analysis and there were no significant effects on QoL based on FACT-G (data not shown).

# Discussion

To control cancer pain, in is necessary prescribe different analgesics depending on the intensity of the pain, referring to the World Health Organization (WH)recommended three-step analgesic lader (WHO, 1996). To treat suddenly occur breakthrough pain, short-acting analges should be prescribed in advance, so mat they can be used when necessary. Begef about analgesics related with patients' op adherence, myths and misconception induged poor pain control. Therefore, patients should be educated on the different methods of pain control and the use of analgesics, as well as instructed on pain assessment and methods of expression to ensure effective control of cancer pain. If the pain of patients can be controlled appropriately following guidelines, unnecessary hospitalization and ER visits will be reduced, resulting in improved quality of life for the patients and a more efficient use of medical expenses. However, a number of obstacles exist for the adequate control of cancer pain. To close gap, several interventions including leadership of cancer care providers and education for patients were emphasized (Nevidjon, 2010). Therefore, we performed a comprehensive systematic literature review and meta-analysis to assess the established rationale of cancer patient education on the use of narcotic analgesics. Our results revealed that the SMDs of the most severe, average, and current pain in the RCTs were significant. In the non-randomized studies, the effects on average pain were significant, but those on worst and current pain were not.

38.0

31.3

10.1

## Yoon Jae Lee et al

Patient-based education reduced the pain of cancer patients, and so could be considered an effective method of cancer pain management. However, these results should be interpreted with caution due to the wide confidence intervals and the heterogeneity of qualitative analysis due to use of different study designs and diverse educational protocols including content, educational tools, measurement tools, and the education time.

In a 2001 review, educational intervention had little effect on the pain levels of patients (Allard et al., 2001). In contrast, a 2009 review suggested that educational intervention reduced the intensity of the average and worst pain compared with normal care or control (Bennett et al., 2009). In this study, patient-based education was also effective at reducing the intensity of cancer pain. Based on these data, patient-based education for the management of cancer pain is highly recommended.

Patient quality of life was assessed using various tools in the included studies, and so a meta-analysis of QoL included only four trials, with no significant effects. Previous systematic reviews suggested that pain medication improved the QoL of cancer patients, and that tramadol significantly improved QoL compared with placebo [assessed using the Activities of Daily Living (ADL) scale (Quigley, 2008)]. In addition, transdermal fentanyl and sustained-release oral morphine improved the QoL of cancer patients (appetite, sleep, daily activities, mental state, emotion, communication, and interest) in six separate trials (Yang et al., 2010). However, we were unable to find any systematic reviews on the effects of patient-based education for QoL. Therefore, further studies are needed to determine the effects of patient education on QoL and provide practical recommendations. In addition, unified measurement tools are required for accurate analysis.

Our study had some limitations. There was significant heterogeneity in the qualitative analysis, because the methods and tools used to educate patients were highly variable, and the individuals in responsible for the education varied between nurses, researchers, physicians, and students. Therefore, meta-analysis of only specific qualified outcomes was possible in some reports. Nevertheless, our data are important, despite these limitations, because our study included non-randomized trials.

In conclusion, educational intervention reduced the pain of cancer patients. Therefore, patient-based education could be an effective management method, and should be strongly recommended. However, to assure positive effects on QoL and prevent patient misunderstanding, studies using standardized protocols should be performed.

# Acknowledgements

The National Evidence-based Healthcare Collaborating Agency (NECA; project no. NA2012-004) funded this study.

# References

Allard P, Maunsell E, Labbé J, Dorval M (2001). Educational

interventions to improve cancer pain control: a systematic review. *J Palliative Med*, **4**, 191-203.

- Aubin M, Vézina L, Parent R, et al (2006). Impact of an educational program on pain management in patients with cancer living at home. *Oncol Nurs Forum*, **33**, 1183-8.
- Bennett MI, Bagnall AM, José Closs S (2009). How effective are patient-based educational interventions in the management of cancer pain? Systematic review and meta-analysis. *Pain*, 143, 192-9.
- Brant JM (2010). The global experience of cancer pain. *Asian Pac J Cancer Prev*, **11**, 7-12.
- Chang MC, Chang YC, Chiou JF, Tsou TS, Lin CC (2002). Overcoming patient-related barriers to cancer pain management for home care patients: a pilot study. *Cancer Nurs*, 25, 470-6.
- de Wit R, van Dam F (2001). From hospital to home care: a randomized controlled trial of a Pain Education Programme for cancer patients with chronic pain. J Adv Nurs, 36, 742-54.
- de Wit R, van Dam F, Zandbelt L, et al (1997). A pain education program for chronic cancer pain patients: follow-up results from a randomized controlled trial. *Pain*, **73**, 55-69.
- Hong SH, Roh SY, Kim SY, et al (2011). Change in cancer pain management in Korea between 2001 and 2006: results of two nationwide surveys. J Pain Symptom Manage, 41, 93-103.
- Keefe FJ, Ahles TA, Sutton L, et al (2005). Partner-guided cancer pain management at the end of life: a preliminary study. J Pain Symptom Manage, 29, 263-72.
- Kim SY, Park JE, Lee YJ, et al (2011). NECA's guidance for undertaking systematic reviews and meta-analyses for intervention. Seoul: National Evidence-based Healthcare Collaborating Agency.
- Kim SY, Park JE, Lee YJ, et al (2013). Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. *J Clin Epidemiol*, **66**, 408-14.
- Kwon IG, Whang MS, Kim JH (2002). Effects of pain management education on pain of the terminal cancer patients at home. J Korean Oncol Nurs, 2, 36-49.
- Lai YH, Guo SL, Keefe FJ, et al (2004). Effects of brief pain education on hospitalized cancer patients with moderate to severe pain. *Supportive Care Cancer*, **12**, 645-52.
- Liang SY, Chen KP, Tsay SL, et al (2013). Relationship between belief about analgesics, analgesic adherence and pain experience in taiwanese cancer outpatients. *Asian Pac J Cancer Prev*, **14**, 713-6.
- Lovell MR, Forder PM, Stockler MR, et al (2010). A randomized controlled trial of a standardized educational intervention for patients with cancer pain. J Pain Symptom Manage, 40, 49-59.
- Miaskowski C, Dodd M, West C, et al (2004). Randomized clinical trial of the effectiveness of a self-care intervention to improve cancer pain management. J Clin Oncol, 22, 1713-20.
- Nevidjon B (2010). Using leadership and advocacy to improve cancer pain management--based on a presentation at the cancer pain, suffering and spirituality course. *Asian Pac J Cancer Prev*, **11**, 13-6.
- Quigley C (2008). Opioids in people with cancer-related pain. Clin Evid (Online), 2008, 2408.
- Shin SB, Lee MH (2003). The effect of cancer pain management education on the pain and the concerns of pain management in cancer patients. *Korean J Rehabil Nurs*, **6**, 90-103.
- Syrjala KL, Abrams JR, Polissar NL, et al (2008). Patient training in cancer pain management using integrated print and video materials: a multisite randomized controlled trial. *Pain*, **135**, 175-86.
- Thomas ML, Elliott JE, Rao SM, et al (2012). A randomized,

clinical trial of education or motivational-interviewing-based coaching compared to usual care to improve cancer pain management. *Oncol Nurs Forum*, **39**, 39-49.

- Vallières I, Aubin M, Blondeau L, Simard S, Giguère A (2006). Effectiveness of a clinical intervention in improving pain control in outpatients with cancer treated by radiation therapy. *Int J Radiat Oncol Biol Phys*, 66, 234-7.
- van der Peet EH, van den Beuken-van Everdingen MH, Patijn J, et al (2009). Randomized clinical trial of an intensive nursing-based pain education program for cancer outpatients suffering from pain. Support Care Cancer, 17, 1089-99.
- Ward S, Donovan HS, Owen B, Grosen E, Serlin R (2000). An individualized intervention to overcome patient-related barriers to pain management in women with gynecologic cancers. *Res Nurs Health*, 23, 393-405.
- Ward SE, Wang KK, Serlin RC, Peterson SL, Murray ME (2009). A randomized trial of a tailored barriers intervention for Cancer Information Service (CIS) callers in pain. *Pain*, 144, 49-56.
- World Health Organization. (1996). Cancer pain relief: with a guide to opioid availability. World Health Organization.
- Yang Q, Xie DR, Jiang ZM, et al (2010). Efficacy and adverse effects of transdermal fentanyl and sustained-release oral morphine in treating moderate-severe cancer pain in Chinese population: a systematic review and meta-analysis. J Exp Clin Cancer Res, 29, 67.
- Yildirim YK, Cicek F, Uyar M (2009). Effects of pain education program on pain intensity, pain treatment satisfaction, and barriers in Turkish cancer patients. *Pain Manag Nurs*, **10**, 220-8.
- Zech DF, Grond S, Lynch J, Hertel D, Lehmann KA (1995). Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. *Pain*, 63, 65-76.